LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.44 2.33

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.44

Máximo

0.44

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+63.04% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9.5M 30M
Abertura anterior	-1.89
Fecho anterior	0.44

Sentimento de Notícias

By Acuity

46%

54%

142 / 345 Ranking em Healthcare

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de mai. de 2026, 08:24 UTC

Grandes Movimentos do Mercado

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 de mai. de 2026, 21:22 UTC

Ganhos

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:01 UTC

Conversa de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 de mai. de 2026, 14:43 UTC

Conversa de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 de mai. de 2026, 14:15 UTC

Conversa de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 de mai. de 2026, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de mai. de 2026, 12:58 UTC

Conversa de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 de mai. de 2026, 12:56 UTC

Conversa de Mercado

Ganhos

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de mai. de 2026, 12:34 UTC

Conversa de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 de mai. de 2026, 12:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero's Assets Look Strategic -- Market Talk

25 de mai. de 2026, 11:00 UTC

Conversa de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 de mai. de 2026, 10:19 UTC

Conversa de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 de mai. de 2026, 10:05 UTC

Ganhos

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 de mai. de 2026, 10:04 UTC

Ganhos

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 de mai. de 2026, 10:03 UTC

Ganhos

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 de mai. de 2026, 10:02 UTC

Ganhos

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 de mai. de 2026, 10:01 UTC

Ganhos

Tenaga Nasional 1Q Net Up 3.7% on Year

25 de mai. de 2026, 10:00 UTC

Ganhos

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q EPS MYR0.1883

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Rev MYR17.1B

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Net MYR1.1B

25 de mai. de 2026, 09:38 UTC

Conversa de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 de mai. de 2026, 08:55 UTC

Conversa de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

63.04% parte superior

Previsão para 12 meses

Média 0.75 USD 63.04%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

142 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.